| SCHEDULE OF SEGMENT INFORMATION |
As
of June 30, 2026, the Company currently has the following reportable segments: Homology of Medicine and Food Series, Computing Power
Product Series, Maca Product Series and others.
SCHEDULE
OF SEGMENT INFORMATION
| | |
Series | | |
Series | | |
Series | | |
Costs | | |
Total | |
| | |
Nine months ended June 30, 2026 | | |
| |
| | |
Business Line | | |
Others | | |
| |
| | |
Homology of Medicine and Food | | |
Computing Power Product | | |
Maca Product | | |
Unallocated Headquarter | | |
| |
| | |
Series | | |
Series | | |
Series | | |
Costs | | |
Total | |
| Revenues, net | |
$ | 1,871,082 | | |
$ | 7,057,088 | | |
$ | 12,226,947 | | |
$ | - | | |
$ | 21,155,117 | |
| Cost of revenue | |
| (1,845,524 | ) | |
| (6,979,946 | ) | |
| (12,227,525 | ) | |
| (476 | ) | |
| (21,053,471 | ) |
| Gross profit | |
| 25,558 | | |
| 77,142 | | |
| (578 | ) | |
| (476 | ) | |
| 101,646 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Operating expenses | |
| (47,537 | ) | |
| (95,259 | ) | |
| (270,238 | ) | |
| (3,859,340 | ) | |
| (4,272,374 | ) |
| Loss from operations | |
| (21,979 | ) | |
| (18,117 | ) | |
| (270,816 | ) | |
| (3,859,816 | ) | |
| (4,170,728 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Fair value variation | |
| - | | |
| - | | |
| - | | |
| (41,286,525 | ) | |
| (41,286,525 | ) |
| Gain on disposal of subsidiary | |
| - | | |
| - | | |
| - | | |
| 14,505 | | |
| 14,505 | |
| Other income | |
| 155 | | |
| 178 | | |
| 1,654 | | |
| 92,066 | | |
| 94,053 | |
| Other expense | |
| (8 | ) | |
| (13 | ) | |
| (90 | ) | |
| (8,070 | ) | |
| (8,181 | ) |
| Segment Loss | |
$ | (21,832 | ) | |
| (17,952 | ) | |
| (269,252 | ) | |
| (45,047,840 | ) | |
| (45,356,876 | ) |
|